Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma

BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is a fatal disease with a dismal response to single-use of immune checkpoint inhibitors (ICIs). ICIs combined with systemic therapy has shown efficacy and safety in various solid tumors. Nab-paclitaxel and gemcitabine (AG), as the standard first-li...

Descripción completa

Detalles Bibliográficos
Autores principales: Shui, Lin, Cheng, Ke, Li, Xiaofen, Shui, Pixian, Zhou, Xiaohan, Li, Jian, Yi, Cheng, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346390/
https://www.ncbi.nlm.nih.gov/pubmed/32646394
http://dx.doi.org/10.1186/s12885-020-07126-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346390/
https://www.ncbi.nlm.nih.gov/pubmed/32646394
http://dx.doi.org/10.1186/s12885-020-07126-3

Ejemplares similares